Viewing Study NCT00134667

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:31 AM
Ignite Modification Date: 2026-05-17 @ 4:30 PM
Study NCT ID: NCT00134667
Status: TERMINATED
Last Update Posted: 2007-01-15
First Post: 2005-08-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Sponsor: Eyetech Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Age-Related Macular Degeneration View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AMD View
None Age-Related Macular Degeneration View
None Macular Degeneration View
None Macugen View
None Photodynamic Therapy View
None PDT View
None Visudyne View
None pegaptanib sodium View
None verteporfin View
None Predominantly Classic View
None Age-Related Macular Degeneration (AMD) View